Dynavax Technologies | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Adma Biologics USD 103.15M 16.44M 2024-12
Amgen USD 11.97B 2.96B 2024-12
AstraZeneca USD 5.49B 691M 2024-12
Biogen USD 2.38B 675.8M 2024-12
BioMarin Pharmaceutical USD 613.22M 324.54M 2024-12
Bristol-Myers Squibb USD 10.88B 529M 2025-03
Dynavax Technologies USD 95.88M 23.45M 2024-12
Gilead Sciences USD 7.93B 2.06B 2025-03
Glaxosmithkline GBP 3.87B 678M 2024-12
Merck USD 13.24B 1.35B 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Pfizer USD 1.04B 49M 2024-12
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Roche Holding CHF 6.98B 2.15B 2024-12
Sarepta Therapeutics USD 1.1B 905.16M 2024-12
TG Therapeutics USD 179.89M 15.93M 2024-12
Vertex Pharmaceuticals USD 4.57B 669.6M 2024-12



Dynavax Technologies Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Apr 2025.